中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
34期
56-57
,共2页
表阿霉素%膀胱癌%治疗%复发预防
錶阿黴素%膀胱癌%治療%複髮預防
표아매소%방광암%치료%복발예방
Epirubicin%Bladder cancer%Treatment%Prevention of recurrence
目的：探讨表阿霉素在膀胱癌治疗及复发预防中的临床效果，总结有益经验为临床用药及治疗实践提供参考。方法：2011年6月-2013年5月收治膀胱癌患者36例，随机分为常规组和观察组，各18例；常规组给予传统膀胱癌治疗方法进行手术治疗和恢复，观察组在常规治疗基础上加予表阿霉素配合治疗；观察两组患者的临床疗效及术后恢复效果。结果：观察组术前表阿霉素灌注后，有效反应11例，有效反应率61.11%；在术后病情复发方面，观察组11.11%，明显低于常规组38.89%，组间差异有统计学意义(P＜0.05)。结论：在膀胱癌疾病治疗及复发预防中，表阿霉素能够提高临床疗效，且未表现出明显不良反应，值得进行更深入的临床讨论和探究。
目的：探討錶阿黴素在膀胱癌治療及複髮預防中的臨床效果，總結有益經驗為臨床用藥及治療實踐提供參攷。方法：2011年6月-2013年5月收治膀胱癌患者36例，隨機分為常規組和觀察組，各18例；常規組給予傳統膀胱癌治療方法進行手術治療和恢複，觀察組在常規治療基礎上加予錶阿黴素配閤治療；觀察兩組患者的臨床療效及術後恢複效果。結果：觀察組術前錶阿黴素灌註後，有效反應11例，有效反應率61.11%；在術後病情複髮方麵，觀察組11.11%，明顯低于常規組38.89%，組間差異有統計學意義(P＜0.05)。結論：在膀胱癌疾病治療及複髮預防中，錶阿黴素能夠提高臨床療效，且未錶現齣明顯不良反應，值得進行更深入的臨床討論和探究。
목적：탐토표아매소재방광암치료급복발예방중적림상효과，총결유익경험위림상용약급치료실천제공삼고。방법：2011년6월-2013년5월수치방광암환자36례，수궤분위상규조화관찰조，각18례；상규조급여전통방광암치료방법진행수술치료화회복，관찰조재상규치료기출상가여표아매소배합치료；관찰량조환자적림상료효급술후회복효과。결과：관찰조술전표아매소관주후，유효반응11례，유효반응솔61.11%；재술후병정복발방면，관찰조11.11%，명현저우상규조38.89%，조간차이유통계학의의(P＜0.05)。결론：재방광암질병치료급복발예방중，표아매소능구제고림상료효，차미표현출명현불량반응，치득진행경심입적림상토론화탐구。
Objective:To explore the clinical effect of the use of epirubicin in the treatment and prevention of recurrence of bladder carcinoma,to summarize the beneficial experience to provide reference for clinical medication and therapy practice. Methods:36 patients with bladder cancer were selected from June 2011 to May 2013.They were randomly divided into the routine group and the observation group with 18 cases in each group.The routine group were given traditional treatment of bladder cancer for operation treatment and recovery.The observation group were given the epirubicin on the basis of routine treatment.We observed clinical efficacy and postoperative recovery effect of the two groups.Results:In the observation group,after the preoperative perfusion of epirubicin,11 cases were effective reaction,and the effective response rate was 61.11% .In the postoperative recurrence of disease,the observation group was 11.11%,which was significantly lower than the conventional group of 38.89%,and the difference was statistically significant(P<0.05).Conclusion:In the treatment of diseases and preventing the recurrence of bladder cancer,epirubicin can improve the clinical efficacy,and there is no obvious adverse reactions.It is worth discussing further and exploration.
